A multicenter retrospective study of PD-1 blockade plus chemotherapy as first-line therapy in advanced hepatoid adenocarcinoma of the stomach
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf312 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Jingru Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330000, P.R.China. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
This study aims to evaluate the efficacy and safety of programmed cell death protein 1 (PD-1) blockade in combination with chemotherapy for patients with advanced hepatoid adenocarcinoma of the stomach (HAS). Materials and methods This study retrospectively collected data from 25 patients with advanced HAS who received first-line PD-1 blockade combined with chemotherapy across 6 centers between January 2018 and January 2024. Progression-free survival and overall survival were assessed using Kaplan-Meier curves.
Results
This study included 25 patients with HAS, all of whom received a first-line treatment regimen combining PD-1 blockade and chemotherapy. The objective response rate and disease control rate were 76.0% and 88.0%, respectively. The median follow-up time was 13.1 months, with a median progression-free survival of 10.2 months (95% CI, 6.3-14.1) and a median overall survival of 20.3 months (95% CI, 11.3-29.4). A total of 20 patients (80.0%) experienced adverse reactions of varying degrees, with white blood cell count decreased (12, 48.0%) being the most common adverse event. Two patients experienced fatal adverse events (grade 5), both of which were unrelated to the PD-1 blockade.
Conclusions
Patients with HAS can derive survival benefits from first-line treatment with PD-1 blockade combined with chemotherapy, and the treatment is well tolerated. Furthermore, this pathological subtype may serve as a predictive indicator of favorable efficacy for PD-1 blockade, regardless of the patients’ programmed death-ligand 1 combined positive score.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330000, P.R.China.
- Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510000, P.R.China.
- Department of Cardiac Vascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou Medical College, Soochow University, Suzhou, Jiangsu 215000, P.R.China.
- Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R.China.
- Department of the Rare Disease Center, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330000, P.R.China.
ORCID-Profile: Jianhua Wu, Xiaojun Xiang
Förderung
- Natural Science Foundation of China
Zitieren
APA
Wang, J., Zhan, J., Rao, Z., Su, G., He, Y., Zhou, L., Wu, J., Sun, X., & Xiang, X. (2025). A multicenter retrospective study of PD-1 blockade plus chemotherapy as first-line therapy in advanced hepatoid adenocarcinoma of the stomach. The Oncologist. https://doi.org/10.1093/oncolo/oyaf312
Vancouver
Wang J, Zhan J, Rao Z, Su G, He Y, Zhou L, et al. A multicenter retrospective study of PD-1 blockade plus chemotherapy as first-line therapy in advanced hepatoid adenocarcinoma of the stomach. The Oncologist. 2025. doi:10.1093/oncolo/oyaf312
BibTeX
@article{Wang2025,
author = {Wang, Jingru and Zhan, Jinbo and Rao, Zhen and Su, Gang and He, Yan and Zhou, Ling and Wu, Jianhua and Sun, Xiaowei and Xiang, Xiaojun},
title = {A multicenter retrospective study of PD-1 blockade plus chemotherapy as first-line therapy in advanced hepatoid adenocarcinoma of the stomach},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf312}
}
EUVIMED